Premature infants : Palivizumab (Synagis®)

Seasonal administration of palivizumab should be considered for infants born at 30 weeks, 0 days or earlier gestation and who are <6 months of age at the beginning of the RSV season (i.e. must be born on or after June 1st, 2022).